Give me a break: oncologists’ perception of systemic treatment holidays

Objective: To analyze physician opinions of, and experiences with patients who take a temporary break from treatment in the setting of metastatic primary or recurrent gynecologic cancer. Methods: An electronic survey was sent to the members of the Society of Gynecologic Oncology (SGO). A treatment holiday was defined as a planned temporary break from systemic treatment in a patient with recurrent or metastatic gynecologic malignancy. Descriptive statistics were calculated using Microsoft Excel, and continuous variables were compared using the Wilcoxon Rank Sum test. Free text responses were qualitatively analyzed. Results: Of the 1314 individuals invited to participate, 74 responded (5.6% response rate). Ninety-six percent of respondents had a patient take a treatment holiday. Ninety-five percent of respondents would offer a treatment holiday for ovarian cancer, 90% for endometrial cancer, 70% for cervical cancer, 57% for vulvar cancer, 52% for vaginal cancer, and 49% for sarcoma. Using a Likert scale, respondents identified life events (86.6%), fatigue from side effects (77.9%), schedule fatigue (67.6%) and desire for “life off treatment” (64.7%) as “very important” reasons for offering a treatment holiday. Patients resumed treatment for return of symptoms (62.9%), progression of disease (60.0%), end of pre-specified break (50%), patient anxiety (45.7%) and recommendation of the physician (11%). 6.8% of physicians experienced regret after a patient underwent a treatment holiday. Ninety-eight percent of respondents agreed that a treatment holiday can be valuable. Conclusion: The gynecologic and medical oncologists who responded to this survey almost uniformly offered their patients treatment holidays, were more likely to offer treatment holidays for ovarian and endometrial cancer, and were unlikely to express regret after the experience.

Chemotherapy holiday; Gynecologic cancer; Treatment holiday

[1] Centers for Disease Control and Prevention, US Department of Health and Human Services: Gynecologic Cancer Incidence, United States–2012–2016. U.S. Cancer Statistics Data Brief: Atlanta, GA. 2019. No 11.

[2] Frey MK, Philips SR, Jeffries J, Herzberg AJ, Harding-Peets GL, Gordon JK, et al. A qualitative study of ovarian cancer survivors’ perceptions of endpoints and goals of care. Gynecologic Oncology. 2014; 135: 261–265.

[3] Tonini G, Imperatori M, Vincenzi B, Frezza AM, Santini D. Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. Journal of Experimental & Clinical Cancer Research. 2013; 32: 92.

[4] Vassileva V, Allen CJ, Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Molecular Cancer Therapeutics. 2008; 7: 630–637.

[5] Muss HB, Case LD, Richards F, White DR, Cooper MR, Cruz JM, et al. Interrupted versus Continuous Chemotherapy in Patients with Metastatic Breast Cancer. New England Journal of Medicine. 1991; 325: 1342–1348.

[6] Onishi T, Sasaki T, Hoshina A. Intermittent Chemotherapy is a Treatment Choice for Advanced Urothelial Cancer. Oncology. 2012; 83: 50–56.

[7] Beer TM, Garzotto M, Henner WD, Eilers KM, Wersinger EM. Intermittent chemotherapy in metastatic androgen-independent prostate cancer. British Journal of Cancer. 2003; 89: 968–970.

[8] Tournigand C, Cervantes A, Figer A, Lledo G, Flesch M, Buyse M, et al. OPTIMOX1: a Randomized Study of FOLFOX4 or FOL- FOX7 with Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—a GERCOR Study. Journal of Clinical Oncol- ogy. 2006; 24: 394–400.

[9] Madariaga A, Rustin GJS, Buckanovich RJ, Trent JC, Oza AM. Wanna Get Away? Maintenance Treatments and Chemotherapy Holidays in Gynecologic Cancers. American Society of Clinical Oncology Educational Book. 2019; 107: e152–e166.